Last reviewed · How we verify

NCT05424406: REACT

Role of Sleep Reactivity in Shift Work Disorder

Recruiting now NA Last updated 14 October 2025
What this trial tests

NA trial testing Active phototherapy in Shift-work Disorder in 150 participants. Currently enrolling.

Timeline
1 January 2023
Primary endpoint
30 June 2027
1 October 2027

Quick facts

Lead sponsorHenry Ford Health System
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designsequential
Maskingdouble
Primary purposeother
Enrollment150
Start date1 January 2023
Primary completion30 June 2027
Estimated completion1 October 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Henry Ford Health System — full company profile →

Who can join

18 and older, any sex, with Shift-work Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this project is to test sleep reactivity as an independent cause of Shift Work Disorder (SWD). The primary hypothesis is that those with high sleep reactivity will show persistent SWD symptoms after experimental reduction of circadian misalignment, which will then be mitigated with CBT.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Shift-work Disorder

Currently open trials in the same condition.

Other Henry Ford Health System trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05424406.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing